Formulations

Bajaj Healthcare bags major approval from DCGI to make API, formulation of antipsychotic drug Pimavanserin

Bajaj Health has also extended the offer for Pimavanserin to several leading pharma companies to ensure availability in Indian market. The company said it has a 'strong manufacturing expertise' which it aims to leverage.

India Pesticides IPO: Should you subscribe?

With momentum building up once again in the primary market, Karunya Rao fills us in on all the things to know regarding the IPO of India Pesticides.

EXCLUSIVE: Over 25 new launches lined up for FY18: Lupin Chief

In an exclusive interview with Moneycontrol‘s Malini Bhupta, Lupin‘s CEO Vinita Gupta says the next year will be good thanks to 25 new product launches.

Laurus Labs expects revenue generation to begin in FY18

The company expects healthy growth going ahead, according to Ravi Kumar, ED and CFO of Laurus Labs, adding that its total debt post the IPO will stand at Rs 750 crore

Ranbaxy jumps 30%; street cheers US base business growth

Analysts say the company's 26 percent sequential growth in US business was a big positive, and a stock re-rating was on the cards following the improvement visible in its base business.

Sun Pharma Q3 net up better-than-expected 32% at Rs 881cr

Sun Pharmaceutical Industries beat street expectations on Friday with a third quarter net profit of Rs 881 crore, up 32 percent year-on-year, helped by strong growth across its businesses, including arm Taro Pharma.

Biocon shrs drop after Q1 net rises lower-than-expected 13%

Biocon shares slipped 2% on Thursday after the biotechnology company reported lower-than-expected first quarter earnings. Its quarterly net profit rose 13% to Rs 79 crore, while net sales rose 30% to Rs 571 crore.

Lupin to set up new formulations manufacturing plant

Drug maker Lupin is setting up a new formulations manufacturing facility at the special economic zone, Mihan in Nagpur.

Lupin Q3 cons net up 5% YoY at Rs 235 cr

Pharma company Lupin's consolidated net profit for the third quarter rose 5% year-on-year at Rs 235.1 crore as strong sales growth was offset by higher tax expenses.

Zydus Cadila buys antibiotics maker Biochem

Zydus Cadila has acquired 100% stake in Mumbai-based antibiotics maker Biochem in efforts to boost its formulations business.

Which pharma cos will gain from the falling rupee? Find out

With nearly half of total revenues coming from exports, the recent sharp deprecation in rupee spells good news the pharma sector. The rupee has depreciated against the US dollar in recent months. It even breached the 54 mark against the US dollar on Thursday and was trading around Rs 54.18 in afternoon session.